ORLANDO, Fla.--(BUSINESS WIRE)--Biotechnology company MabCure, Inc. (OTCBB: MBCI) is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists (SGO).
